Journal of Clinical Oncology, Vol 23, No 10 (April 1), 2005: pp. 2346-2357
© 2005 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2005.00.240
Adoptive Cell Transfer Therapy Following Non-Myeloablative but Lymphodepleting Chemotherapy for the Treatment of Patients With Refractory Metastatic Melanoma
Mark E. Dudley,
John R. Wunderlich,
James C. Yang,
Richard M. Sherry,
Suzanne L. Topalian,
Nicholas P. Restifo,
Richard E. Royal,
Udai Kammula,
Don E. White,
Sharon A. Mavroukakis,
Linda J. Rogers,
Gerald J. Gracia,
Stephanie A. Jones,
David P. Mangiameli,
Michelle M. Pelletier,
Juan Gea-Banacloche,
Michael R. Robinson,
David M. Berman,
Armando C. Filie,
Andrea Abati,
Steven A. Rosenberg
From the Surgery Branch; Experimental Immunology and Transplantation Branch; Laboratory of Pathology, Center for Cancer Research, National Cancer Institute; National Eye Institute, National Institutes of Health, Bethesda, MD
Address reprint requests to Steven A. Rosenberg, MD, PhD, Surgery Branch, National Cancer Institute, NIH, CRC 3-3940, 10 Center Dr MSC 1201, Bethesda MD 20892-1202; e-mail: sar{at}mail.nih.gov
PURPOSE: We investigated the combination of lymphodepleting chemotherapy followed by the adoptive transfer of autologous tumor reactive lymphocytes for the treatment of patients with refractory metastatic melanoma.
PATIENTS AND METHODS: Thirty-five patients with metastatic melanoma, all but one with disease refractory to treatment with high-dose interleukin (IL) -2 and many with progressive disease after chemotherapy, underwent lymphodepleting conditioning with two days of cyclophosphamide (60 mg/kg) followed by five days of fludarabine (25 mg/m2). On the day following the final dose of fludarabine, all patients received cell infusion with autologous tumor-reactive, rapidly expanded tumor infiltrating lymphocyte cultures and high-dose IL-2 therapy.
RESULTS: Eighteen (51%) of 35 treated patients experienced objective clinical responses including three ongoing complete responses and 15 partial responses with a mean duration of 11.5 ± 2.2 months. Sites of regression included metastases to lung, liver, lymph nodes, brain, and cutaneous and subcutaneous tissues. Toxicities of treatment included the expected hematologic toxicities of chemotherapy including neutropenia, thrombocytopenia, and lymphopenia, the transient toxicities of high-dose IL-2 therapy, two patients who developed Pneumocystis pneumonia and one patient who developed an Epstein-Barr virusrelated lymphoproliferation.
CONCLUSION: Lymphodepleting chemotherapy followed by the transfer of highly avid antitumor lymphocytes can mediate significant tumor regression in heavily pretreated patients with IL-2 refractory metastatic melanoma.
Authors' disclosures of potential conflicts of interest are found at the end of this article.
This article has been cited by other articles:

|
 |

|
 |
 
H. L. Kaufman, H.-J. Lenz, J. Marshall, D. Singh, C. Garett, C. Cripps, M. Moore, M. von Mehren, R. Dalfen, W. J. Heim, et al.
Combination Chemotherapy and ALVAC-CEA/B7.1 Vaccine in Patients with Metastatic Colorectal Cancer
Clin. Cancer Res.,
August 1, 2008;
14(15):
4843 - 4849.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Wei, A. B. Shreiner, N. Takeshita, L. Chen, W. Zou, and A. E. Chang
Tumor-Induced Immune Suppression of In vivo Effector T-Cell Priming Is Mediated by the B7-H1/PD-1 Axis and Transforming Growth Factor {beta}
Cancer Res.,
July 1, 2008;
68(13):
5432 - 5438.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
O. J. Finn
Cancer Immunology
N. Engl. J. Med.,
June 19, 2008;
358(25):
2704 - 2715.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. R. Kalli, C. J. Krco, L. C. Hartmann, K. Goodman, M. J. Maurer, C. Yu, E. M. Johnson, C. L. Erskine, M. L. Disis, P. J. Wettstein, et al.
An HLA-DR-Degenerate Epitope Pool Detects Insulin-like Growth Factor Binding Protein 2-Specific Immunity in Patients with Cancer
Cancer Res.,
June 15, 2008;
68(12):
4893 - 4901.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Wallace, V. Kapoor, J. Sun, P. Mrass, W. Weninger, D. F. Heitjan, C. June, L. R. Kaiser, L. E. Ling, and S. M. Albelda
Transforming Growth Factor-{beta} Receptor Blockade Augments the Effectiveness of Adoptive T-Cell Therapy of Established Solid Cancers
Clin. Cancer Res.,
June 15, 2008;
14(12):
3966 - 3974.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. C. Palmer, C.-C. Chan, L. Gattinoni, C. Wrzesinski, C. M. Paulos, C. S. Hinrichs, D. J. Powell Jr., C. A. Klebanoff, S. E. Finkelstein, R. N. Fariss, et al.
From the Cover: Effective tumor treatment targeting a melanoma/melanocyte-associated antigen triggers severe ocular autoimmunity
PNAS,
June 10, 2008;
105(23):
8061 - 8066.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. C. Tumeh, C. G. Radu, and A. Ribas
PET Imaging of Cancer Immunotherapy
J. Nucl. Med.,
June 1, 2008;
49(6):
865 - 868.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Z. Sebestyen, E. Schooten, T. Sals, I. Zaldivar, E. San Jose, B. Alarcon, S. Bobisse, A. Rosato, J. Szollosi, J. W. Gratama, et al.
Human TCR That Incorporate CD3{zeta} Induce Highly Preferred Pairing between TCR{alpha} and {beta} Chains following Gene Transfer
J. Immunol.,
June 1, 2008;
180(11):
7736 - 7746.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. K. Darcy
IL-21 priming enhances T-cell immunotherapy
Blood,
June 1, 2008;
111(11):
5268 - 5269.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. S. Hinrichs, R. Spolski, C. M. Paulos, L. Gattinoni, K. W. Kerstann, D. C. Palmer, C. A. Klebanoff, S. A. Rosenberg, W. J. Leonard, and N. P. Restifo
IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy
Blood,
June 1, 2008;
111(11):
5326 - 5333.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Coccoris, E. Swart, M. A. de Witte, J. W. J. van Heijst, J. B. A. G. Haanen, K. Schepers, and T. N. M. Schumacher
Long-Term Functionality of TCR-Transduced T Cells In Vivo
J. Immunol.,
May 15, 2008;
180(10):
6536 - 6543.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Kline, I. E. Brown, Y.-Y. Zha, C. Blank, J. Strickler, H. Wouters, L. Zhang, and T. F. Gajewski
Homeostatic Proliferation Plus Regulatory T-Cell Depletion Promotes Potent Rejection of B16 Melanoma
Clin. Cancer Res.,
May 15, 2008;
14(10):
3156 - 3167.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Maury, C. Cordonnier, M. Kuentz, D. Klatzmann, and J. L. Cohen
Searching for factors to improve the antileukemic effect of donor lymphocyte infusion
Blood,
May 15, 2008;
111(10):
5256 - 5256.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. King, J. Waxman, and H. Stauss
Advances in tumour immunotherapy
QJM,
May 13, 2008;
(2008)
hcn050v1.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
O. Goldberger, I. Volovitz, A. Machlenkin, E. Vadai, E. Tzehoval, and L. Eisenbach
Exuberated Numbers of Tumor-Specific T Cells Result in Tumor Escape
Cancer Res.,
May 1, 2008;
68(9):
3450 - 3457.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Schlom, J. L. Gulley, and P. M. Arlen
Paradigm Shifts in Cancer Vaccine Therapy
Experimental Biology and Medicine,
May 1, 2008;
233(5):
522 - 534.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Worschech, M. Kmieciak, K. L. Knutson, H. D. Bear, A. A. Szalay, E. Wang, F. M. Marincola, and M. H. Manjili
Signatures Associated with Rejection or Recurrence in HER-2/neu-Positive Mammary Tumors
Cancer Res.,
April 1, 2008;
68(7):
2436 - 2446.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Jorritsma, A. D. Bins, T. N.M. Schumacher, and J. B.A.G. Haanen
Skewing the T-Cell Repertoire by Combined DNA Vaccination, Host Conditioning, and Adoptive Transfer
Cancer Res.,
April 1, 2008;
68(7):
2455 - 2462.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Machlenkin, R. Uzana, S. Frankenburg, G. Eisenberg, L. Eisenbach, J. Pitcovski, R. Gorodetsky, A. Nissan, T. Peretz, and M. Lotem
Capture of Tumor Cell Membranes by Trogocytosis Facilitates Detection and Isolation of Tumor-Specific Functional CTLs
Cancer Res.,
March 15, 2008;
68(6):
2006 - 2013.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Fujita, X. Zhu, K. Sasaki, R. Ueda, K. L. Low, I. F. Pollack, and H. Okada
Inhibition of STAT3 Promotes the Efficacy of Adoptive Transfer Therapy Using Type-1 CTLs by Modulation of the Immunological Microenvironment in a Murine Intracranial Glioma
J. Immunol.,
February 15, 2008;
180(4):
2089 - 2098.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Mirmonsef, G. Tan, G. Zhou, T. Morino, K. Noonan, I. Borrello, and H. I. Levitsky
Escape from suppression: tumor-specific effector cells outcompete regulatory T cells following stem-cell transplantation
Blood,
February 15, 2008;
111(4):
2112 - 2121.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. B. Heimberger, W. Sun, S. F. Hussain, M. Dey, L. Crutcher, K. Aldape, M. Gilbert, S. J. Hassenbusch, R. Sawaya, B. Schmittling, et al.
Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: Case study
Neuro-oncol,
February 1, 2008;
10(1):
98 - 103.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. A. Marques, P. S. Hahnel, C. Wolfel, S. Thaler, C. Huber, M. Theobald, and M. Schuler
An immune escape screen reveals Cdc42 as regulator of cancer susceptibility to lymphocyte-mediated tumor suppression
Blood,
February 1, 2008;
111(3):
1413 - 1419.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Barber, T. Zhang, and C. L. Sentman
Immunotherapy with Chimeric NKG2D Receptors Leads to Long-Term Tumor-Free Survival and Development of Host Antitumor Immunity in Murine Ovarian Cancer
J. Immunol.,
January 1, 2008;
180(1):
72 - 78.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Jorritsma, R. Gomez-Eerland, M. Dokter, W. van de Kasteele, Y. M. Zoet, I. I. N. Doxiadis, N. Rufer, P. Romero, R. A. Morgan, T. N. M. Schumacher, et al.
Selecting highly affine and well-expressed TCRs for gene therapy of melanoma
Blood,
November 15, 2007;
110(10):
3564 - 3572.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. H. Yi, H. Nechushtan, W. J. Bowers, G. R. Walker, Y. Zhang, D. G. Pham, E. R. Podack, H. J. Federoff, K. A. Tolba, and J. D. Rosenblatt
Adoptively Transferred Tumor-Specific T Cells Stimulated Ex vivo Using Herpes Simplex Virus Amplicons Encoding 4-1BBL Persist in the Host and Show Antitumor Activity In vivo
Cancer Res.,
October 15, 2007;
67(20):
10027 - 10037.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. N. Kochenderfer and R. E. Gress
A Comparison and Critical Analysis of Preclinical Anticancer Vaccination Strategies
Experimental Biology and Medicine,
October 1, 2007;
232(9):
1130 - 1141.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. M. Wong, R. R. Scotland, R. L. Lau, C. Wang, A. J. Korman, W. M. Kast, and J. S. Weber
Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs
Int. Immunol.,
October 1, 2007;
19(10):
1223 - 1234.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. K. Choi, Y. H. Kim, W. J. Kang, S. K. Lee, K. H. Kim, S. M. Shin, W. M. Yokoyama, T. Y. Kim, and B. S. Kwon
Mechanisms Involved in Synergistic Anticancer Immunity of Anti-4-1BB and Anti-CD4 Therapy
Cancer Res.,
September 15, 2007;
67(18):
8891 - 8899.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Lizee, M. A. Cantu, and P. Hwu
Less Yin, More Yang: Confronting the Barriers to Cancer Immunotherapy
Clin. Cancer Res.,
September 15, 2007;
13(18):
5250 - 5255.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. H. Wrzesinski, Y. Y. Wan, and R. A. Flavell
Transforming Growth Factor-{beta} and the Immune Response: Implications for Anticancer Therapy
Clin. Cancer Res.,
September 15, 2007;
13(18):
5262 - 5270.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. M. Paulos, A. Kaiser, C. Wrzesinski, C. S. Hinrichs, L. Cassard, A. Boni, P. Muranski, L. Sanchez-Perez, D. C. Palmer, Z. Yu, et al.
Toll-like Receptors in Tumor Immunotherapy
Clin. Cancer Res.,
September 15, 2007;
13(18):
5280 - 5289.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. F. McDermott and M. B. Atkins
More Support for the Judicious Use of High-Dose Interleukin-2 in Patients With Advanced Melanoma
J. Clin. Oncol.,
September 1, 2007;
25(25):
3791 - 3793.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Mizukami, T. Hanagiri, M. Yasuda, K. Kuroda, Y. Shigematsu, T. Baba, T. Fukuyama, Y. Nagata, T. So, Y. Ichiki, et al.
Antitumor Effect of Antibody against a SEREX-Defined Antigen (UOEH-LC-1) on Lung Cancer Xenotransplanted into Severe Combined Immunodeficiency Mice
Cancer Res.,
September 1, 2007;
67(17):
8351 - 8357.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Matter, V. Pavelic, D. D. Pinschewer, S. Mumprecht, B. Eschli, T. Giroglou, D. von Laer, and A. F. Ochsenbein
Decreased Tumor Surveillance after Adoptive T-Cell Therapy
Cancer Res.,
August 1, 2007;
67(15):
7467 - 7476.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. J. Pittet, J. Grimm, C. R. Berger, T. Tamura, G. Wojtkiewicz, M. Nahrendorf, P. Romero, F. K. Swirski, and R. Weissleder
In vivo imaging of T cell delivery to tumors after adoptive transfer therapy
PNAS,
July 24, 2007;
104(30):
12457 - 12461.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Schlom, P. M. Arlen, and J. L. Gulley
Cancer Vaccines: Moving Beyond Current Paradigms
Clin. Cancer Res.,
July 1, 2007;
13(13):
3776 - 3782.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Hsu, S. A. Jones, C. J. Cohen, Z. Zheng, K. Kerstann, J. Zhou, P. F. Robbins, P. D. Peng, X. Shen, T. J. Gomes, et al.
Cytokine-independent growth and clonal expansion of a primary human CD8+ T-cell clone following retroviral transduction with the IL-15 gene
Blood,
June 15, 2007;
109(12):
5168 - 5177.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. M. Curtsinger, M. Y. Gerner, D. C. Lins, and M. F. Mescher
Signal 3 Availability Limits the CD8 T Cell Response to a Solid Tumor
J. Immunol.,
June 1, 2007;
178(11):
6752 - 6760.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L.-X. Wang, S. Shu, M. L. Disis, and G. E. Plautz
Adoptive transfer of tumor-primed, in vitro activated, CD4+ T effector cells (TEs) combined with CD8+ TEs provides intratumoral TE proliferation and synergistic antitumor response
Blood,
June 1, 2007;
109(11):
4865 - 4876.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Zhao, M. R. Parkhurst, Z. Zheng, C. J. Cohen, J. P. Riley, L. Gattinoni, N. P. Restifo, S. A. Rosenberg, and R. A. Morgan
Extrathymic Generation of Tumor-Specific T Cells from Genetically Engineered Human Hematopoietic Stem Cells via Notch Signaling
Cancer Res.,
March 15, 2007;
67(6):
2425 - 2429.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. O. Butler, J.-S. Lee, S. Ansen, D. Neuberg, F. S. Hodi, A. P. Murray, L. Drury, A. Berezovskaya, R. C. Mulligan, L. M. Nadler, et al.
Long-Lived Antitumor CD8+ Lymphocytes for Adoptive Therapy Generated Using an Artificial Antigen-Presenting Cell
Clin. Cancer Res.,
March 15, 2007;
13(6):
1857 - 1867.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Dang, K. L. Knutson, V. Goodell, C. dela Rosa, L. G. Salazar, D. Higgins, J. Childs, and M. L. Disis
Tumor Antigen-Specific T-Cell Expansion Is Greatly Facilitated by In vivo Priming
Clin. Cancer Res.,
March 15, 2007;
13(6):
1883 - 1891.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. N. Lopez, C. Pereda, M. Ramirez, A. Mendoza-Naranjo, A. Serrano, A. Ferreira, R. Poblete, A. M. Kalergis, R. Kiessling, and F. Salazar-Onfray
Melanocortin 1 Receptor Is Expressed by Uveal Malignant Melanoma and Can Be Considered a New Target for Diagnosis and Immunotherapy
Invest. Ophthalmol. Vis. Sci.,
March 1, 2007;
48(3):
1219 - 1227.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. F. Costa, K. Le Blanc, and B. Brodin
Concise Review: Cancer/Testis Antigens, Stem Cells, and Cancer
Stem Cells,
March 1, 2007;
25(3):
707 - 711.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Bracci, F. Moschella, P. Sestili, V. La Sorsa, M. Valentini, I. Canini, S. Baccarini, S. Maccari, C. Ramoni, F. Belardelli, et al.
Cyclophosphamide Enhances the Antitumor Efficacy of Adoptively Transferred Immune Cells through the Induction of Cytokine Expression, B-Cell and T-Cell Homeostatic Proliferation, and Specific Tumor Infiltration
Clin. Cancer Res.,
January 15, 2007;
13(2):
644 - 653.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. R. Riddell
Engineering Antitumor Immunity by T-Cell Adoptive Immunotherapy
Hematology,
January 1, 2007;
2007(1):
250 - 256.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. C. Wehler, M. Nonn, B. Brandt, C. M. Britten, M. Grone, M. Todorova, I. Link, S. A. Khan, R. G. Meyer, C. Huber, et al.
Targeting the activation-induced antigen CD137 can selectively deplete alloreactive T cells from antileukemic and antitumor donor T-cell lines
Blood,
January 1, 2007;
109(1):
365 - 373.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. C. Yang and R. Childs
Immunotherapy for Renal Cell Cancer
J. Clin. Oncol.,
December 10, 2006;
24(35):
5576 - 5583.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Kausche, T. Wehler, E. Schnurer, V. Lennerz, W. Brenner, S. Melchior, M. Grone, M. Nonn, S. Strand, R. Meyer, et al.
Superior Antitumor In vitro Responses of Allogeneic Matched Sibling Compared with Autologous Patient CD8+ T Cells
Cancer Res.,
December 1, 2006;
66(23):
11447 - 11454.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Montagna, R. Maccario, F. Locatelli, E. Montini, S. Pagani, F. Bonetti, L. Daudt, I. Turin, D. Lisini, C. Garavaglia, et al.
Emergence of antitumor cytolytic T cells is associated with maintenance of hematologic remission in children with acute myeloid leukemia
Blood,
December 1, 2006;
108(12):
3843 - 3850.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Mackensen, N. Meidenbauer, S. Vogl, M. Laumer, J. Berger, and R. Andreesen
Phase I Study of Adoptive T-Cell Therapy Using Antigen-Specific CD8+ T Cells for the Treatment of Patients With Metastatic Melanoma
J. Clin. Oncol.,
November 1, 2006;
24(31):
5060 - 5069.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Markel, R. Seidman, N. Stern, T. Cohen-Sinai, O. Izhaki, G. Katz, M. Besser, A. J. Treves, R. S. Blumberg, R. Loewenthal, et al.
Inhibition of Human Tumor-Infiltrating Lymphocyte Effector Functions by the Homophilic Carcinoembryonic Cell Adhesion Molecule 1 Interactions
J. Immunol.,
November 1, 2006;
177(9):
6062 - 6071.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. A. Stoklasek, K. S. Schluns, and L. Lefrancois
Combined IL-15/IL-15R{alpha} Immunotherapy Maximizes IL-15 Activity In Vivo
J. | |